On the Frontlines of Psoriasis

Unlocking the Potential of TYK2 Inhibitors in Plaque Psoriasis

15 min · 16. jan. 2026
episode Unlocking the Potential of TYK2 Inhibitors in Plaque Psoriasis cover

Description

Guest: Christopher Bunick, MD, PhD, FAAD Host: Ryan Quigley With high selectivity, durable response, and once-daily dosing, next-generation TYK2 inhibitors offer a promising oral option for patients with moderate-to-severe plaque psoriasis. Ryan Quigley sits down with Dr. Christopher Bunick, Associate Professor of Dermatology and Translational Biomedicine at Yale University School of Medicine, to learn more about how these agents may align with evolving patient preferences and expand options beyond injectables.

Comments

0

Be the first to comment

Sign up now and become a member of the On the Frontlines of Psoriasis community!

Get Started

1 month for 9 kr.

Then 99 kr. / month · Cancel anytime.

  • Podcasts kun på Podimo
  • 20 lydbogstimer pr. måned
  • Gratis podcasts

All episodes

28 episodes